SOURCE: Barrier Therapeutics, Inc.

May 02, 2007 07:30 ET

Barrier Therapeutics to Release First Quarter 2007 Financial Results on May 10, 2007

Company to Host Conference Call on May 10, 2007 at 5:00 p.m. ET

PRINCETON, NJ -- (MARKET WIRE) -- May 2, 2007 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the first quarter of 2007 on Thursday, May 10, 2007 at approximately 4:00 p.m. ET. The company will host a conference call on May 10 at 5:00 p.m. ET to provide a company update and discuss the financial results for the quarter. Interested investors can listen to the call live over the Internet on the investor relations section of the company's web site located at http://www.barriertherapeutics.com or by dialing 800-798-2801 (U.S.) or 617-614-6205 (International) and using conference ID code: 62901348.

What:   Barrier Therapeutics, Inc. First Quarter 2007 Corporate Update and
        Financial Results Conference Call

When:   Thursday, May 10, 2007 at 5:00 p.m. ET

Where:  The investor relations section of the Company's web site located at
        http://www.barriertherapeutics.com

How:    Live over the Internet -- Simply log on to the web at the address
        above, or dial 800-798-2801 (U.S.) or 617-614-6205 (International).
        Conference ID code: 62901348.
An audio replay of the call will be available for seven days by dialing 888-286-8010 (U.S.) or 617-801-6888 (International). Replay Passcode: 44627039.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solagé® (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.

Xolegel, Vusion and Solagé are trademarks of Barrier Therapeutics, Inc.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    EVP & CFO
    (609) 945-1202

    Lazar Partners Ltd.
    Gregory Gin
    Investor Relations
    (212) 867-1762